

Prof. UMUT KEFELİ

Personal Information

Email: umut.kefeli@kocaeli.edu.tr

Web: <https://avesis.kocaeli.edu.tr/umut.kefeli>

International Researcher IDs

ScholarID: z8sabHwAAAAJ

ORCID: 0000-0001-6126-5377

Publons / Web Of Science ResearcherID: V-6023-2018

Yoksis Researcher ID: 142246

Education Information

Post Doctorate of Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Kartal Dr.Lütfi Kırdar Eğitim Ve Araştırma Hastanesi, Turkey 2009 - 2012

Expertise In Medicine, Marmara University, School Of Medicine, Turkey 2003 - 2008

Foreign Languages

English, B2 Upper Intermediate

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Kocaeli University, Tip Fakültesi, Dahili Tip Bilimleri, 2019 - Continues

Associate Professor, Kocaeli University, Tip Fakültesi, Dahili Tip Bilimleri, 2016 - 2019

Assistant Professor, Kocaeli University, Tip Fakültesi, Dahili Tip Bilimleri, 2014 - 2016

Courses

ÜRİNER SİSTEM TÜMÖRLERİ, Undergraduate, 2016 - 2017

BAŞ ve BOYUN KANSERLERİ, Undergraduate, 2016 - 2017

KEMOTERAPİ İLAÇLARI, Undergraduate, 2016 - 2017

Published journal articles indexed by SCI, SSCI, and AHCI

- I. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Almuradova E., Seyyar M., Arak H., Tamer F., Kefeli U., Koca S., Sen E., Telli T. A., Karatas F., Gokmen I., et al.

- INTERNATIONAL JOURNAL OF CANCER, vol.154, no.4, pp.692-700, 2024 (SCI-Expanded)
- II. **Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent ¹⁷⁷Lu-PSMA-617**
Şahin E., Kefeli U., Zorlu Ş., Seyyar M., Ozkorkmaz Akdag M., Can Sancı P., Karakayali A., Ucuncu Kefeli A., Bakkal Temi Y., Cabuk D., et al.
MEDICINE, vol.102, no.47, 2023 (SCI-Expanded)
- III. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**
Unal C., Azizy A., KARABULUT S., Tastekin D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., ÇOBAN E., EVRENSEL T., Kalkan Z., et al.
ONCOLOGIST, vol.28, pp.875-884, 2023 (SCI-Expanded)
- IV. **The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas**
Aydin D., KEFELİ U., Ozcelik M., Erdem G. U., SENDUR M. A. N., Yildirim M. E., Oven B. B., BİLİMİ A., Gumus M.
Medicina (Lithuania), vol.59, no.8, 2023 (SCI-Expanded)
- V. **NUTRISCORE Compared to NRS-2002 for Detection of Malnutrition in Hospitalized Cancer Patients; A Cross Sectional Study**
Kefeli A., Seyyar M., ŞAHİN E., SARPER E. B., KEFELİ U.
Nutrition and Cancer, vol.75, no.8, pp.1619-1624, 2023 (SCI-Expanded)
- VI. **Surgical, pathological and clinical features of advanced colorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data**
Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., Simsek E. T., Arslan C., Dane F., Celik S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- VII. **Perceptions and acceptance of telemedicine among medical oncologists before and during the COVID-19 pandemic in Turkey**
Sahin E., Kefeli U., Cabuk D., Ozden E., Cakmak Y., Kaypak M. A., Seyyar M., Uygun K.
SUPPORTIVE CARE IN CANCER, vol.29, no.12, pp.7497-7503, 2021 (SCI-Expanded)
- VIII. **Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase**
Özden E., Çakmak Y., Uslu H., Tosun M., Şahin E., Kaypak M. A., Çabuk D., Kefeli U., Uygun K.
Annals Of Oncology, vol.31, pp.90-91, 2020 (SCI-Expanded)
- IX. **Follicular lymphoma in a patient with splenosis: a case report**
Kefeli U., Mehtap Ö., Cakir Ö., Eruyar A. T., İsgoren S., Ucuncu K.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019 (SCI-Expanded)
- X. **Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.**
Aydin D., Sendur M., Kefeli U., Unal O., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B., Uysal M., et al.
Clinical colorectal cancer, vol.16, pp.220-227, 2017 (SCI-Expanded)
- XI. **Netrin-1 in cancer: Potential biomarker and therapeutic target?**
Kefeli U., Ucuncu K., Cabuk D., Isik U., Sonkaya A., Acikgoz O., Ozden E., Uygun K.
TUMOR BIOLOGY, vol.39, no.4, 2017 (SCI-Expanded)
- XII. **Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.**
Aydin D., Sendur M., Kefeli U., Ustaalioglu B., Aydin O., Yildirim E., Isik D., Ozcelik M., Surmeli H., Oyman A., et al.
Clinical colorectal cancer, vol.16, pp.78-83, 2017 (SCI-Expanded)
- XIII. **The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker.**
Yıldırım M., Kefeli U., Aydin D., Sener N., Gümüş M.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.37, pp.11903-11907, 2016 (SCI-Expanded)
- XIV. **Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).**

- Süner A., Aydin D., Hacıoğlu M., Doğu G., İmamoğlu G., Menekşe S., Pilancı K., Yazıcı Ö., Koca D., Karaağaç M., et al. European review for medical and pharmacological sciences, vol.20, pp.1238-43, 2016 (SCI-Expanded)
- XV. **Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology**
Ciltas A., Buyukberber S., Topcu T. O., Kucukoner M., Uyeturk U., Cihan S., Sendur M. A., Budakoglu B., Kefeli U., Yıldız R., et al. UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.96-102, 2016 (SCI-Expanded)
- XVI. **Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).**
Aydin D., Sendur M., Kefeli U., Umut U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Bala U., Sener D., et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, pp.1242-1249, 2016 (SCI-Expanded)
- XVII. **Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study.**
Bayraktar B., Ozemir I., Kefeli U., Demiral G., Sagiroğlu J., Bayraktar O., Adali G., Ozcelik A., Tortum O. World journal of gastroenterology, vol.21, pp.9373-9, 2015 (SCI-Expanded)
- XVIII. **Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.**
Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D., et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.17, pp.604-11, 2015 (SCI-Expanded)
- XIX. **Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.**
Basak O., Aker V., Bilici A., Gurleyik G., Erkol B., Kefeli U., Aliustaoglu M. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.879-86, 2014 (SCI-Expanded)
- XX. **Non-small cell lung cancer in women: A distinct entity?**
Kefeli U., Oven Ustaalioglu B. B., Yilmaz B., Aydin D., Sener N., Aliustaoglu M., Gumus M. Gazi Medical Journal, vol.25, no.3, pp.92-96, 2014 (SCI-Expanded)
- XXI. **Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.**
Kefeli U., Benekli M., Sevinc A., Yildiz R., Kaplan M., Ciltas A., Balakan O., Isikdogan A., Coskun U., Dane F., et al. Oncology letters, vol.6, pp.605-611, 2013 (SCI-Expanded)
- XXII. **Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.**
Korkmaz T., Seber S., Kefeli U., Sari E., Canhoroz M., Oven B., Yildirim E., Yasar N., Aydin D., Balvan O., et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.15, pp.535-40, 2013 (SCI-Expanded)
- XXIII. **Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.**
Kefeli U., Buyuberber S., Akyol M., Yildiz R., Kaplan M., Ciltas A., Sevinc A., Karaca H., Seker M., Ozdemir N., et al. Hepato-gastroenterology, vol.60, pp.647-52, 2013 (SCI-Expanded)
- XXIV. **The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.**
Ustaalioglu B., Bilici A., Kefeli U., Şeker M., Oncel M., Gezen C., Gumus M., Demirelli F. American journal of clinical oncology, vol.35, pp.580-6, 2012 (SCI-Expanded)
- XXV. **Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment.**
Kefeli U., Yildirim M., Aydin D., Madenci O., Yasar N., Sener N., Mert A., Yuksel S., Ercelep O., Korkmaz T., et al. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, vol.17, pp.663-7, 2012 (SCI-Expanded)
- XXVI. **Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.**
Eser M., Kement M., Balin S., Coskun C., Kefeli U., Gumus M., Altuntas Y., Kurt N., Mayadagli A.

- World journal of surgical oncology, vol.10, pp.180, 2012 (SCI-Expanded)
- XXVII. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis**
- Bozduk H., Abali H., Coskun S., Aydiner A., Çinkaya A., Demirkazik A., Özeturk A., Yolcu A., Balkan A., Çavdar A., et al.
World Journal of Surgical Oncology, vol.10, 2012 (SCI-Expanded)
- XXVIII. Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.**
- Kaya A., Coskun U., Ozkan M., Sevinc A., Yilmaz A., Gumus M., Unal O., Ozdemir N., Alici S., Berk V., et al.
Onkologie, vol.35, pp.576-80, 2012 (SCI-Expanded)
- XXIX. Evaluation of Hodgkin lymphoma cases and determination of prognostic factors Hodgkin lenfoma olguları{dotless}ni{dotless}n retrospektif değerlendirilmesi ve prognostik faktörlerin saptanması{dotless}**
- Seker M., Meng A., Bilici A., Ustaalioglu B. B., Kefeli U., Özseker N. I., Mayadağlı A., Salepçi T., Gümüş M.
Turk Onkoloji Dergisi, vol.26, no.3, pp.108-114, 2011 (SCI-Expanded)
- XXX. Tissue and serum adiponectin levels in patients with gastric cancer: are there any correlations between adiponectin levels and histopathological variables?**
- Seker M., Bilici A., Guler D., Ustaalioglu B., Gozu H., Erkal F., Sonmez B., Karaduman M., Kefeli U., Yildirim E., et al.
Hepato-gastroenterology, vol.58, pp.1841-6, 2011 (SCI-Expanded)
- XXXI. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience**
- Kefeli U., Kaya S., Ustaalioglu B., Bilici A., Kefeli A., Yildirim M., Seker M., Yilmaz B., Salepçi T., Uygun K., et al.
MEDICAL ONCOLOGY, vol.28, no.3, pp.661-666, 2011 (SCI-Expanded)
- XXXII. F-18 FDG PET/CT imaging and bronchoscopic image of tracheal recurrence in patient with non-small-cell lung cancer.**
- Oven U., Kefeli U., Bilici A., Ustaalioglu R., Seker M., Cinaral F., Dogusoy I.
Clinical nuclear medicine, vol.36, pp.367-9, 2011 (SCI-Expanded)
- XXXIII. A retrospective analysis of women's chances to become pregnant after completion of chemotherapy: a single center experience.**
- Oven U., Bilici A., Kefeli U., Seker M., Salepçi T., Unal O., Gumus M.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.16, pp.349-52, 2011 (SCI-Expanded)
- XXXIV. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.**
- Ustaalioglu B., Seker M., Bilici A., Canpolat N., Yildirim E., Kefeli U., Ustaalioglu R., Yilmaz B., Salepçi T., Ozdemir N., et al.
Medical oncology (Northwood, London, England), vol.28, pp.258-64, 2011 (SCI-Expanded)
- XXXV. A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy**
- Kefeli U., Bilici A., Ustaalioglu B., Kefeli A., Yildirim M., Seker M., Gumus M.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.283, no.2, pp.405-407, 2011 (SCI-Expanded)
- XXXVI. The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?**
- Bilici A., Ustaalioglu B., Seker M., Kefeli U., Canpolat N., Tekinsoy B., Ozugur S., Gumus M.
European journal of nuclear medicine and molecular imaging, vol.38, pp.64-73, 2011 (SCI-Expanded)
- XXXVII. Pulmonary toxicity in patients receiving docetaxel chemotherapy**
- Yumuk P., Kefeli U., Ceyhan B., Dane F., Eroglu B., Gumus M., Cabuk D., Basaran G., Abacioglu U., Turhal N.
MEDICAL ONCOLOGY, vol.27, no.4, pp.1381-1388, 2010 (SCI-Expanded)
- XXXVIII. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection.**
- Bilici A., Seker M., Ustaalioglu B., Kefeli U., Yildirim E., Yavuzer D., Aydin F., Salepçi T., Oncel M., Gumus M.
Annals of surgical oncology, vol.17, pp.2037-44, 2010 (SCI-Expanded)
- XXXIX. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.**
- Seker M., Ustaalioglu B., Bilici A., Yildirim M., Kefeli U., Barisik N., Tamer I., Gumus M.

- Leukemia research, vol.34, 2010 (SCI-Expanded)
- XL.** Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience.
 Oven U., Gumus M., Bilici A., Seker M., Ustaalioglu R., Kefeli U., Salepçi T., Canpolat N., Mayadagli A., Dogusoy I. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.15, pp.529-36, 2010 (SCI-Expanded)
- XLI.** Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer?
 Bilici A., Ustaalioglu B., Gumus M., Seker M., Yilmaz B., Kefeli U., Yildirim E., Sonmez B., Salepçi T., Kement M., et al. Onkologie, vol.33, pp.101-5, 2010 (SCI-Expanded)
- XLII.** Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
 Oven U., Bilici A., Kefeli U., Seker M., Yildirim E., Salepçi T., Oncel M., Kement M., Gumus M. Oncology, vol.79, pp.105-11, 2010 (SCI-Expanded)
- XLIII.** Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer.
 Kefeli U., Dane F., Yumuk P., Karamanoglu A., Iyikesici S., Basaran G., Turhal N. European journal of cancer care, vol.18, pp.191-4, 2009 (SCI-Expanded)
- XLIV.** Psychosocial predictors of co-morbid somatization syndrome in dyspepsia
 Kuscu M., Imeryuz N., Celenk O., Asena E., Kiziltas S., Tanrikulu A., KEFELİ U. JOURNAL OF PSYCHOSOMATIC RESEARCH, no.1, pp.35, 2005 (SCI-Expanded)

Articles Published in Other Journals

- I. Two Case of Breast Carcinoma Developing Reactive Axillary Lymphadenopathy After CoronaVac (Sinovac) Vaccine
 ŞAHİN E., ÇABUK D., YAPRAK BAYRAK B., ÇALIŞKAN F., ARSLAN A. S., ÖNESU Z., CAPA B., BAKKAL TEMİ Y., KEFELİ U., UYGUN K. Open Access Journal of Oncology and Medicine, vol.5, no.3, pp.581-584, 2023 (Peer-Reviewed Journal)
- II. RELATIONSHIPS OF BODY MASS INDEX WITH PROGNOSTIC FACTORS AND SURVIVAL IN ENDOMETRIAL CANCER
 YENİHAYAT E. M., KEFELİ U., ÇABUK D., İŞIK U., ÖZDEN E., çakmak y., UYGUN K. Acta medica nicomedia, vol.3, no.3, pp.94-99, 2020 (Peer-Reviewed Journal)
- III. Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer
 KEFELİ U., Kaymaz S., Aydin D., Isik D., ÇABUK D., Sonkaya A., Acikgoz O., İŞIK U., ÖZDEN E., UYGUN K. BEZMIALEM SCIENCE, vol.7, no.4, pp.265-270, 2019 (ESCI)
- IV. Prognostic Factors for Operated Gallbladder Cancer.
 Oven U., Bilici A., Seker M., Kefeli U., Aydin D., Celik S., Demir T., Erkol B. Journal of gastrointestinal cancer, vol.50, pp.451-457, 2019 (ESCI)
- V. Akciğer kanserinde sağkalımı etkileyen klinikopatolojik özellikler
 KEFELİ U., USTAALIOĞLU B. B., YILDIRIM M. E., ERKOL B., AYDIN D., ŞENER N., SONKAYA A., AÇIKGÖZ Ö. mARMARA mEDICAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (Scopus)
- VI. Clinicopathological factors related to survival in lung cancer
 KEFELİ U., Oven Ustaalioglu B. B., Yildirim M. E., Erkol B., Aydin D., Sener N., Sonkaya A., Acikgoz O. MARMARA MEDICAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (ESCI)
- VII. İnflamatuvar Meme Kanseri Serimiz Tek Merkez Deneyimi
 Ustaalioglu B. B., BİLİZİ A., ŞEKER M., Salepçi T., Yıldırım E., KEFELİ U., Kement M., GÜMÜŞ M. Acta Oncologica Turcica, vol.42, no.3, pp.93-99, 2009 (Peer-Reviewed Journal)
- VIII. NADİR BİR NAZOLAKRİMAL HEMANJİYOPERİSTOM OLGSU
 Ustaalioglu B. B., ŞEKER M., BİLİZİ A., Erkol B., KEFELİ U., Yıldırım E., SÖNMEZ B., GÜMÜŞ M., Salepçi T.

Refereed Congress / Symposium Publications in Proceedings

- I. **Metastatik Küçük Hücreli Dışı Akciğer Kanserli Hastaların Nivolumab İle Sağkalım Sonuçlarının Değerlendirilmesi**
BAKKAL TEMİ Y., KEFELİ U., UYGUN K.
Onkolojide Yenilikler Sempozyumu, Turkey, 27 - 29 October 2023
- II. **ABİRATERON VE ENZALUTAMİD: POST-DOSETAKSEL METASTATİK KASTRASYON DİRENÇLİ PROSTAT KANSERİ TEDAVİSİNDE BENZER ETKİNLİK, TEK MERKEZ DENEYİMİ**
Bakkal Temi Y., Kefeli U., Uygun K.
13th International Medicine and Heath Sciences Researches Congress, Ankara, Turkey, 26 - 27 August 2023, pp.240
- III. **Abirateron ve Enzalutamid: Post-Dosetaksel Metastatik Kastrasyon Dirençli Prostat Kanseri Tedavisinde Benzer Etkinlik, Tek Merkez Deneyimi**
BAKKAL TEMİ Y., KEFELİ U., UYGUN K.
13. Uluslararası Tıp ve Sağlık Bilimleri Araştırmaları Kongresi, 26 - 27 August 2023
- IV. **MEME KANSERİNDE ATİPİK PREZENTASYON, OLGU SUNUMU**
ÖZKORKMAZ AKDAĞ M., SEYYAR M., CAN ŞANCI P., KARAKAYALI A., ŞAHİN E., BAKKAL TEMİ Y., ÇABUK D., KEFELİ U., UYGUN K.
26-30 NİSAN 2023 10. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023
- V. **NADİR BİR VAKA: MEMENİN PRİMER NÖROENDOKRİN TÜMÖRÜ OLGUSU**
CAN ŞANCI P., KARAKAYALI A., ÖZKORKMAZ AKDAĞ M., SEYYAR M., ÇABUK D., KEFELİ U., BAKKAL TEMİ Y., UYGUN K.
26-30 NİSAN 2023 10. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023
- VI. **TRASTUZUMAB DERUXTECAN'A BAĞLI GELİŞEN PNÖMONİT OLGUSU**
SEYYAR M., ŞAHİN E., CAN ŞANCI P., Özorkmaz M. A., Karakayali A., Bakkal Temi Y., Çabuk D., Kefeli U., Uygun K.
26-30 NİSAN 2023 10. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023
- VII. **MEME KANSERİNDE NADİR BİR PARANEOPLASTİK SENDROM, OLGU SUNUMU**
KARAKAYALI A., SEYYAR M., CAN ŞANCI P., ÖZKORKMAZ AKDAĞ M., ŞAHİN E., BAKKAL TEMİ Y., ÇABUK D., KEFELİ U., UYGUN K.
26-30 NİSAN 2023 10. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Ankara, Turkey, 26 - 30 April 2023
- VIII. **Metastatik Renal Hücreli Karsinomda Birinci Seri Sunitinib Ve Pazopanibin Böbrek Fonksiyonlarına Etkisi**
BAKKAL TEMİ Y., ŞAHİN E., SEYYAR M., ÖZKORKMAZ AKDAĞ M., CAN ŞANCI P., KARAKAYALI A., KEFELİ U., ÇABUK D., UYGUN K.
13-16 NİSAN 2023 HEDEF KANSER 2023, Girne, Cyprus (Kktc), 13 - 16 April 2023
- IX. **YASSI EPİTEL HÜCRELİ AKCİĞER KARSİNOMU OLGUSUNDA 12 YIL SONRA GELİŞEN KÜÇÜK HÜCRELİ KARSİNOM TRANSFORMASYONU**
Can Şancı P., Şahin E., Özorkmaz Akdağ M., Karakayali A., Seyyar M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.
9. Ulusal Akciğer Kanseri Kongresi, Antalya, Turkey, 16 - 19 December 2021, no.8, pp.90
- X. **ADO-TRASTUZUMAB EMTANSİN TEDAVİSİ İLE UZUN SÜRELİ YANIT GÖRÜLEN BİR METASTATİK MEME KARSİNOMU OLGUSU**
Şahin E., Seyyar M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.
8. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.207, pp.114
- XI. **BRCA MUTASYONLU HASTALARIN KLINİKOPATOLOJİK ÖZELLİKLERİ**
Şahin E., Çabuk D., Gökbayrak M., Çine N., Özden E., Seyyar M., Kaypak M. A., Çakmak Y., Işık U., Kefeli U., et al.
8. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.187, pp.112

- XII. POSTMENOPAZAL MEME KANSERİ HASTALARINDA ADJUVAN AROMATAZ İNHİBİTÖRLERİNİN VÜCUT KİTLÉ İNDEKSİNE GÖRE SAĞKALIMA ETKİSİ**
Şahin E., Şafak Ö., Çabuk D., Özden E., Işık U., Kefeli U., Uygun K.
8. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.193, pp.113
- XIII. CORONAVAC (SİNÖVAC) AŞISI SONRASINDA REAKTİF AKSİLLER LENFADENOPATİ GELİŞEN İKİ MEME KARSİNOMU OLGUSU**
Şahin E., Kaypak M. A., Yaprak Bayrak B., Çalışkan F., Arslan A. S., Seyyar M., Çakmak Y., Çabuk D., Kefeli U., Uygun K.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, no.186, pp.111
- XIV. Geç tanı alan bir melanom olgusu**
ŞAHİN E., SEYYAR M., ŞİMŞEK E. E., ÖZÇELİK M., KAYPAK M. A., ÇAKMAK Y., BAKKAL TEMİ Y., KEFELİ U., ÇABUK D., UYGUN K.
13-17 EKİM 2021 5. ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2021
- XV. Geç tanı alan bir melanom olgusu**
Şahin E., Seyyar M., Elen Şimşek E., Özçelik M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.
5. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.10-11
- XVI. Metastatik küçük hücreli akciğer kanseri (khak) tanılı hastada atezolizumaba bağlı nadir bir yan etki: miyozit**
Şahin E., Seyyar M., Çabuk D., Yazıcı A., Tuncer F., Kaypak M. A., Çakmak Y., Kefeli U., Uygun K.
5. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.10-11
- XVII. Dabrafenib+trametinibe bağlı grade 4 nötropeni olgusu**
Seyyar M., Şahin E., Kaypak M. A., Çakmak Y., Kefeli U., Çabuk D., Uygun K.
5. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.20
- XVIII. Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase**
Ozden E., Isik U., Cakmak Y., Uslu H., Tosun M., Sahin E., Kaypak M., Cabuk D., Kefeli U., Uygun K.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31
- XIX. The effect of chemotherapy on survival applied in the last term of life in cancer patients**
IŞIK U., Erol A., Cakmak Y., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K., Simsek M.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XX. Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.**
Isik U., Kostek O., Demiray G., Dirican A., Simsek M., Buyuksimsek M., Ucar G., Gunaydin U. M., Sakalar T., Aliyev A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXI. Erken evre Seminom'xxda Radyoterap mi, Kemoterapi mi?**
KEFELİ U.
2. Ulusal Ürogenital Kanserler Kongresi, Turkey, 11 - 14 October 2018
- XXII. Metastatik Renal Hücreli Karsinom Tek Merkez Deneyimi**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
2. Ulusal Ürogenital Kanserler Kongresi, Turkey, 11 - 14 October 2018
- XXIII. PRİMER İNCE BARSAK MALİGN MELANOM OLGUSU**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
7. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018
- XXIV. J Gastrointest Cancer The prognostic factors for operated gallbladder cancer**
ÖVEN B. B., ŞEKER M., KEFELİ U., aydın d.
ESMO World Congress on Gastrointestinal Cancer 2017, 28 June - 01 July 2017
- XXV. Meme kanseri hastalarının klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi ve sağkalım analizleri**
ÇABUK D., geçgel f., SONKAYA A., açıkgoz ö., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVI. Akciğer kanseri olgularının klinik patolojik ve moleküler özellikleri ve sağkalım ilişkisi**

- ÇABUK D., dündar e., SONKAYA A., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVII. **Kliniğimizdeki mide kanserli hastaların klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi**
ÇABUK D., kaymaz s., KEFELİ U., SONKAYA A., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVIII. **KOLOREKTAL KANSER HASTALARINDA ADJUVAN XELOX ve FOLFOX REJİİMLERİNİN RETROSPEKTİF KARŞILAŞTIRILMASI ATOD ÇALIŞMASI**
Uncu D., DANE F., Demir H., Menekşe S., Topçu Öztürk T., KEFELİ U., Pilancı Nur K., Baykara M., Ulaş A., Ustaalioğlu B., et al.
12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015
- XXIX. **NÜKS BAZAL HÜCRE KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN PET BT İLE GÖSTERİLMESİ OLGU SUNUMU**
Kefeli Üçüncü A., KEFELİ U.
12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015
- XXX. **NÜKS BAZAL HÜCRELİ KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN FDG-PET/BT İLE GÖSTERİLMESİ OLGU SUNUMU**
ÜÇÜNCÜ KEFELİ A., KEFELİ U.
12.ULUSAL TİBBİ ONKOLOJİ KONGRESİ, Turkey, 16 September 2015
- XXXI. **Altmış Beş Yaş Üstü Rezektabl Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Adjuvan Tedavi Analizi**
KEFELİ U., Açıkgöz Ö., SONKAYA A., ÇABUK D., Temel Gül A., ÖZBAY S., YILDIZ D. K., UYGUN K.
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015
- XXXII. **CLINICAL IMPORTANCE OF DISCORDANCE IN HORMONE RECEPTOR AND HER2/NEU STATUS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER**
Ustaalioglu B. B. O., Vardar F. A., Bilici A., Gurleyik G., Erkol B., Kefeli U.
39th ESMO Congress (ESMO), Madrid, Spain, 26 - 30 September 2014, vol.25
- XXXIII. **Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology**
Demirci U., Oflazoglu U., Kodaz H., Ciltas A., Kefeli U., Akyol M., Ozturk B., Geredell C., Seker M. M., Clhan S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXIV. **COMPARISON OF SECOND LINE TREATMENT OUTCOMES BETWEEN SENSITIVE AND REFRACTORY SMALL CELL LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS**
Korkmaz T., Seber S., SARI E., Canhoroz M., Ustaalioglu B. O., Kefeli U., Balvan O., Gumus M., Yasar N., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.497-498
- XXXV. **PLASMA M30 AND M65 LEVELS IN PATIENTS WITH ADVANCED GASTRIC CANCER: IS THERE AN IMPACT ON SURVIVAL OF PATIENTS?**
Bilici A., Ustaalioglu B. B. O., Orcun A., Ercan S., Seker M., Kefeli U., Yilmaz B. E., Yildirim M. E., Gezen C., Gumus M.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.48
- XXXVI. **SERUM M30 AND M65 VALUES IN PATIENTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER COMPARED WITH HEALTHY CONTROL GROUP**
Ustaalioglu B. O., Bilici A., Ercan S., Orcun A., Seker M., Kefeli U., Ozkan A., Yilmaz B. E., Yildirim M. E., Gumus M.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.72-73
- XXXVII. **Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer**
BİLİMİ A., USTAALİOĞLU B., GÜMÜŞ M., ŞEKER M., ERKOL B., SÖNMEZ B., YILDIRIM M. E., KEFELİ U., SALEPÇİ T., KEMENT M.
2010 Gastrointestinal Cancers Symposium, United States Of America, 22 - 24 January 2010
- XXXVIII. **THE IMPORTANCE OF LIVER METASTASECTOMY IN METASTATIC COLORECTAL CANCER PATIENTS:**

SINGLE CENTER EXPERIENCES

Ustaalioglu O. B., Seker M., Bilici A., Salepcı T., Kefeli U., Oncel M., Yıldırım E., Yılmaz B., Kement M., Gümüş M.

12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 30 June - 03 July 2010, vol.21, pp.68

XXXIX. Pulmonary toxicity in patients receiving docetaxel chemotherapy

Kefeli U., YUMUK P. F., CEYHAN B., DANE F., Eroglu B., Cabuk D., Basaran G., Teomete M., Turhal N. S.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

XL. The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).

Iyikesici M., Kefeli U., Basaran G., Dane F., Ekenel M., Yumuk P., Turhal N.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

Other Publications

I. Abiraterona Bağlı Gelişen Hipotirodizm Olgusu

Seyyar M., Şahin E., Kaypak M. A., Can Şancı P., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.54, 2022

II. OKSALIPLATİNE BAĞLI HIPERAMONYEMİK ENSEFALOPATİ OLGUSU

Kaypak M. A., Şahin E., Seyyar M., Karakayali A., Can Şancı P., Özkarımkaz Akdağ M., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.189-190, 2022

III. TARAMA TESTİ İLE LOKAL İLERİ EVREDE SAPTANAN KOLONUN BÜYÜK HÜCRELİ NÖROENDOKRİN KARSINOM OLGUSU

Can Şancı P., Seyyar M., Özkarımkaz Akdağ M., Karakayali A., Şahin E., Kaypak M. A., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.153-154, 2022

IV. PAZOPANİBE BAĞLI HIPOGLISEMI OLGUSU

Fındıklı G., Seyyar M., Kaypak M. A., Şahin E., Can Şancı P., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.224-225, 2022

V. CA 15-3 YÜKSEKLİĞİ İLE PROGRESYON SAPTANAN MEME KANSERİ OLGUSU

Seyyar M., Şahin E., Kaypak M. A., Can Şancı P., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.232, 2022

VI. TANI KONULDUKTAN 2 YIL SONRA OPERE OLAN LUMINAL A MEME KANSERİ OLGUSU

Bırol K., Seyyar M., Şahin E., Can Şancı P., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.228, 2022

Supported Projects

ÜÇÜNCÜ KEFELİ A., AKSU M. G., KEFELİ U., VURAL Ç., Suyusal H. İ., Project Supported by Higher Education Institutions, Uterin Seröz Kanserde Netrin1 Ekspresyonu Yeni Bir Biyomarker Olabilir Mi?, 2022 - 2023

KEFELİ U., ÖZGÜN Ö., Project Supported by Higher Education Institutions, KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERLİ HASTALARDA ADAM17 EKSPRESYONU VE SAĞKALIMLA İLİŞKİSİ, 2018 - 2020

Metrics

Publication: 98

Citation (WoS): 464

Citation (Scopus): 495

H-Index (WoS): 12

H-Index (Scopus): 13

Non Academic Experience

İSTANBUL GÖZTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ
SÜREYYAPAŞA MESLEK HASTALIKLARI HASTANESİ